BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ: CELG) announced that results from the Southwest Oncology Group (SWOG) Phase III randomized, controlled trial evaluating REVLIMID (lenalidomide) and the steroid dexamethasone were presented for the first time at the 49th annual American Society of Hematology (ASH) Meeting. The SWOG (S0232) study (Abstract #77) evaluated the combination therapy of REVLIMID and dexamethasone in patients with newly diagnosed multiple myeloma and found that patients given the treatment regimen had superior response rates and progression-free survival compared to those who received dexamethasone alone.
